---
title: Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes
nct_id: NCT06927947
overall_status: RECRUITING
phase: NA
sponsor: University of Michigan Rogel Cancer Center
study_type: INTERVENTIONAL
primary_condition: Hereditary Malignant Neoplasm
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06927947.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06927947"
ct_last_update_post_date: 2025-10-16
last_seen_at: "2026-05-12T06:43:11.013Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes

**Official Title:** Testing Effectiveness of Navigation Interventions to Increase Uptake of Cascade Genetic Testing Among Relatives of Individuals Diagnosed With Hereditary Cancer Syndromes

**NCT ID:** [NCT06927947](https://clinicaltrials.gov/study/NCT06927947)

## Key Facts

- **Status:** RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 500
- **Lead Sponsor:** University of Michigan Rogel Cancer Center
- **Conditions:** Hereditary Malignant Neoplasm, Hereditary Neoplastic Syndrome
- **Start Date:** 2025-09-23
- **Completion Date:** 2026-09-30
- **CT.gov Last Update:** 2025-10-16

## Brief Summary

This clinical trial tests whether various web-based tools can help improve communication about hereditary cancer risk in families and decrease barriers to genetic testing for relatives of patients with hereditary cancer syndromes. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or certain cancers diagnosed in biological relatives may mean patients are more likely to have a genetic change. Once a genetic change is identified in a family, other biological relatives can choose to undergo testing themselves to better understand their cancer risk. The uptake of genetic testing in other biological relatives once a genetic condition is identified is about 20% to 30%. The Cascade Genetic Testing Platform is a virtual tool that seeks to overcome barriers related to logistics of family communication and improve dissemination of genetic testing information which is clinically actionable for individuals at highest risk for cancer. Using the Cascade Genetic Testing Platform may improve ways to share information about hereditary risk with biological relatives.

## Detailed Description

03JUN2025- Amendment was approved that shorten the study timeline from 12 to 6 months. We believe this is sufficient to capture our primary outcome (participation) and a shorter timeline may keep participants more engaged.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* PROBANDS: Clinically confirmed autosomal dominant pathogenic germline variant (PGV) associated with a hereditary cancer syndrome
* PROBANDS: Previous evaluation by the University of Michigan (U-M) Cancer Genetics Clinic
* PROBANDS: ≥ 18 years old
* PROBANDS: Able to speak and read English
* PROBANDS: Access to the internet
* RELATIVES: Biological relative of proband
* RELATIVES: ≥ 18 years old
* RELATIVES: Able to speak and read English
* RELATIVES: Access to the internet
* RELATIVES: Have not completed germline genetic testing, per self-report at baseline

Exclusion Criteria:

* RELATIVES: Prior clinical germline genetic testing for cancer or already have an upcoming appointment scheduled with a genetics provider, per self-report at baseline
```

## Arms

- **Prevention (Cascade Genetic Testing Platform)** (EXPERIMENTAL) — PROBANDS: Probands use the relative invitation tool to invite at-risk relatives to participate.

RELATIVES: Participants receive access to the virtual Cascade Genetic Testing Platform, which includes a Genetic Testing Family Letter and access to the VGN. The Genetic Testing Family Letter provides information about the genetic diagnosis in the family, instructions for the relatives on how to schedule a genetic evaluation, and contact information for the U-M Cancer Genetics Clinic. The VGN is an interactive web-based tool that provides personalized information addressing readiness, barriers and motivators to testing, and knowledge, and presents educational content about genetic testing and information about testing options, including how to access them on study.

## Interventions

- **Communication Intervention** (OTHER) — Use relative invitation tool
- **Health Promotion and Education** (OTHER) — Receive access to the VGN
- **Informational Intervention** (OTHER) — Receive access to a Genetic Testing Family Letter
- **Survey Administration** (OTHER) — Ancillary studies

## Primary Outcomes

- **Percentage of probands that utilize the invitation tool** _(time frame: Up to 6 Months)_ — Will be defined as inviting at least 1 eligible at-risk relative. Will be assessed using descriptive statistics. Will be tabulated and summarized. Continuous variables will be summarized by mean, median, and standard deviation; histograms and boxplots will be used to further assess distributional characteristics of these variables. Categorical variables will be tabulated with frequencies and percentages. Will be estimated and presented along with a 95% confidence interval.
- **Percentage of invited relatives that engage** _(time frame: Up to 6 Months)_ — Will be defined as enrolling in the study and accessing the informational content (letter and/or virtual genetics navigator) at least 1 time. Will be assessed using descriptive statistics. Will be tabulated and summarized. Continuous variables will be summarized by mean, median, and standard deviation; histograms and boxplots will be used to further assess distributional characteristics of these variables. Categorical variables will be tabulated with frequencies and percentages. Will be estimated and presented along with a 95% confidence interval.

## Secondary Outcomes

- **Extent of utilization of the invitation portal by probands** _(time frame: Up to 6 Months)_
- **Percentage of relatives invited who subsequently enroll in the study** _(time frame: Up to 6 Months)_
- **Percentage of relative participants who have either scheduled or completed genetic testing** _(time frame: Up to 3 months)_

## Locations (1)

- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of michigan comprehensive cancer center|ann arbor|michigan|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06927947.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06927947*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*